Revlimid (lenalidomide)
Multiple myeloma
CommercialApproved
Key Facts
About Bristol Myers Squibb
Bristol Myers Squibb operates as a premier global biopharmaceutical company with a mission to transform patients' lives through science. The company maintains leadership positions in oncology, hematology, cardiovascular, and immunology therapeutic areas with blockbuster products and innovative treatment modalities. BMS employs a research strategy rooted in causal human biology and diverse platform technologies to deliver first- and best-in-class medicines to patients worldwide.
View full company profileTherapeutic Areas
Other Multiple myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Darzalex (daratumumab) | Johnson & Johnson | Approved |
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| REGN5458 | Regeneron Pharmaceuticals | Phase 1/2 |
| Ninlaro (ixazomib) | Takeda Pharmaceutical | Commercial |
| Tecvayli (teclistamab) | Genmab | Approved |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |
| YH29407 | Yuhan | Phase 1 |